Clinical trials
Completed Lymphoma, Non-Hodgkin trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
111 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 12 |
| 2012 | 6 |
| 2013 | 9 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 9 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 111 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 9 |
| Hoffmann-La Roche | 9 |
| Bayer | 5 |
| Institut Paoli-Calmettes | 5 |
| Novartis Pharmaceuticals | 5 |
| Pfizer | 5 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Genentech, Inc. | 4 |
| Gilead Sciences | 4 |
| Janssen Research & Development, LLC | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Non-Hodgkin | 111 |
| Lymphoma, Follicular | 26 |
| Lymphoma, Large B-Cell, Diffuse | 25 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 21 |
| Lymphoma | 21 |
| Lymphoma, Mantle-Cell | 17 |
| Hodgkin Disease | 15 |
| Recurrence | 15 |
| Lymphoma, B-Cell, Marginal Zone | 12 |
| Lymphoma, B-Cell | 11 |
Trials
Showing 1 to 25 of 111. Each trial links to its page on Pharma Observatory.
11 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.